Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026
Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Fineline Cube Jul 1, 2026
Company Drug

Boehringer Ingelheim’s Zongertinib Earns Breakthrough Designation in China for HER2-Mutated NSCLC

Fineline Cube Aug 13, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has received a significant endorsement from China’s Center...

Legal / IP Policy / Regulatory

China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry

Fineline Cube Aug 13, 2024

The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment

Fineline Cube Aug 13, 2024

IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...

Company Drug

Ascendis Pharma’s Hypoparathyroidism Therapy Yorvipath Wins FDA Nod, Fills Market Gap

Fineline Cube Aug 13, 2024

This week, the U.S. Food and Drug Administration (FDA) granted market approval to Ascendis Pharma...

Company Deals

Siemens Healthineers Partners with Cedars-Sinai to Boost Medical Cooperation and Education

Fineline Cube Aug 13, 2024

Siemens Healthineers AG, a global leader in medical technology, has announced a strategic partnership with...

Company Medical Device

Artech Medical’s Balloon Cryoablation Catheter Wins NMPA Nod for Atrial Fibrillation Treatment

Fineline Cube Aug 13, 2024

Shanghai Artech Medical Technology Co., Ltd., a company known for its innovation in the medical...

Hospital

Former Hainan Medical University President Li Jingquan Expelled for Serious Disciplinary Violations

Fineline Cube Aug 13, 2024

Hainan’s disciplinary inspection committee has announced the expulsion of Li Jingquan, the former president of...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Shows Strong Protection in Immunocompromised Adults, Phase III Sub-Study Reveals

Fineline Cube Aug 13, 2024

Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline...

Company Deals

TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion

Fineline Cube Aug 12, 2024

TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial...

Company Drug

Chinese NMPA Approves Hengrui Pharmaceuticals’ Generic Abraxane for Metastatic Pancreatic Cancer Treatment

Fineline Cube Aug 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Mindray Medical Forges Comprehensive Partnership with CUHK-Shenzhen School of Medicine

Fineline Cube Aug 12, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a prominent medical device company based in...

Company Drug

CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Clinical Trials in Systemic Lupus Erythematosus

Fineline Cube Aug 12, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company in China, has announced that...

Company Drug

Mabwell’s Nectin-4 Targeting ADC 9MW2821 on Path to Breakthrough Designation in China for Urothelial Carcinoma

Fineline Cube Aug 12, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Shineyo Medical Secures RMB 100 Million in Series A+ Funding for Cardiac and Vascular Devices

Fineline Cube Aug 12, 2024

Shineyo Medical, a Shanghai-based manufacturer of electrophysiological and peripheral interventional devices, has reportedly secured nearly...

Company Drug

Fujian Cosunter’s Innovative Drug GST-HG141 Exceeds Efficacy in Reducing HBV DNA in Phase II Study

Fineline Cube Aug 12, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced the successful...

Company Drug

3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608

Fineline Cube Aug 12, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau

Fineline Cube Aug 12, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced...

Company Drug

3SBio’s Subsidiary Achieves Milestone in Phase II Study for Chronic Sinusitis Treatment SSGJ-611

Fineline Cube Aug 12, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Lee’s Pharma Subsidiary Receives Green Light for Phase III Dry Eye Study and Completes Myopia Trial

Fineline Cube Aug 12, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a prominent Chinese pharmaceutical company, through its subsidiary Zhaoke...

Company

Amgen to Establish New Site in Hyderabad, India, with Focus on Technology and Digital Innovation

Fineline Cube Aug 12, 2024

Amgen (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has announced strategic plans...

Posts pagination

1 … 338 339 340 … 689

Recent updates

  • Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification
  • Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
  • Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Company Drug

Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication

Company Drug

Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.